{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'interaction study data in IMPs with', '-', 'Contraception during', 'demonstrated or suspected human', 'treatment and until the end of', 'teratogenicity fetotoxicity,', 'relevant systemic exposure', 'recommendation for use of hormonal', '-', 'Additional pregnancy', 'contraceptives should be thoroughly', 'testing to be considered; as a', 'justified by the sponsor. Additional', 'minimum, at the end of', 'contraceptive methods, including', 'relevant systemic exposure', 'supplementary barrier methods, may be', '-', 'In each case of delayed', 'considered.', 'menstrual period (over 1', 'Females of childbearing potential are', 'month between', 'defined as:', 'menstruations), confirmation', 'not surgically (documented', 'of absence of pregnancy is', 'hysterectomy, bilateral oophorectomy,', 'strongly recommended This', 'or bilateral salpingectomy) or', 'recommendation also applies', 'congenitally sterile', 'to women of childbearing', 'not postmenopausalpostmenarchal', 'potential with infrequent or', 'or > 12 years of age', 'irregular menstrual cycles.', 'Description of', 'Highly effective birth control', 'differentRecommendations for', 'methods:', 'application of birth control methods:', 'Highly effective birth control', 'IMP (TEV-50717) with possible', 'methods that can achieve a', 'human teratogenicity/fetotoxicity', 'failure rate of less than 1% per', 'year when used consistently and', '-', 'Highly effective method of', 'correctly are considered. Such', 'contraception', 'methods include:', '-', 'Contraception during treatment', 'and until the end of relevant', 'Combined estrogen and', 'systemic exposure', 'progestogen hormonal', 'contraception (oral, intravaginal,', '-', 'Additional pregnancy testing to', 'transdermal) associated with', 'be considered; as a minimum, at', 'inhibition of ovulation; these', 'the end of relevant systemic', 'should be initiated at least 1', 'exposure', 'month before the first dose of', '-', 'In each case of delayed', 'IMP.', 'menstrual period (over 1 month', 'Progestogen-only hormonal', 'between menstruations),', 'contraception (oral, injectable,', 'confirmation of absence of', 'implantable) associated with', 'pregnancy is strongly', 'inhibition of ovulation; these', 'recommended. This', 'should be initiated at least before', 'recommendation also applies to', 'the first dose of IMP.', 'women of childbearing potential', 'with infrequent or irregular', 'Unacceptable birth control', 'methods:', 'menstrual cycles.', 'Periodic abstinence (calendar,', 'Highly effective birth control', 'methods:', 'symptothermal, post-ovulation', 'methods), withdrawal (coitus', 'Highly effective birth control methods', 'interruptus), spermicides only,', 'that can achieve a failure rate of less', 'and lactational amenorrhoea', 'than 1% per year when used', '169']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'consistently and correctly are', 'method (LAM) are not acceptable', 'considered. Such methods include:', 'methods of contraception. Female', 'Combined estrogen and', 'condom and male condom should', 'progestogen hormonal contraception', 'not be used together.', '(oral, intravaginal, transdermal)', 'Pregnancy tests in females of', 'associated with inhibition of ovulation;', 'childbearing potential:', 'these should be initiated at least 7 days', '1. Consider additional', '(for IMPs without suspected', 'pregnancy testing, but at least at', 'teratogenicity/genotoxicity) and 1', 'the end of relevant systemic', 'month (for IMPs potentially', 'exposure.', 'teratogenie/genotexie) before the first', 'dose of IMP.', 'Progestogen-only hormonal', 'contraception (oral, injectable,', 'implantable) associated with inhibition', 'of ovulation; these should be initiated', 'at least 7 days (for IMPs without', 'suspected eratogenicity/genotoxicity', 'and 1 month (for IMPs potentially', 'teratogenie/genotoxie) before the first', 'dose of IMP.', 'Acceptable birth control methods:', 'Acceptable birth control methods that', 'result in a failure rate of more than 1%', 'per year include: progestogen only oral', 'hormonal contraception for which the', 'inhibition of ovulation is not the', 'primary mode of action; male or', 'female condom with or without', 'spermicide; cap, diaphragm, or sponge', 'with spermicide The combination of', 'male condom with either cap,', 'diaphragm, or sponge with spermicide', '(double barrier methods) are also', 'considered acceptable but not highly', 'effective methods of birth control.', 'Unacceptable birth control methods:', 'Periodic abstinence (calendar,', 'symptothermal, post-ovulation', 'methods), withdrawal (coitus', 'interruptus), spermicides only, and', 'lactational amenorrhoea method', '(LAM) are not acceptable methods of', 'contraception. Female condom and', 'male condom should not be used', 'together.', '170']\n\n###\n\n", "completion": "END"}